JP2023517043A - ヒト免疫不全ウイルスの複製阻害剤 - Google Patents

ヒト免疫不全ウイルスの複製阻害剤 Download PDF

Info

Publication number
JP2023517043A
JP2023517043A JP2022553213A JP2022553213A JP2023517043A JP 2023517043 A JP2023517043 A JP 2023517043A JP 2022553213 A JP2022553213 A JP 2022553213A JP 2022553213 A JP2022553213 A JP 2022553213A JP 2023517043 A JP2023517043 A JP 2023517043A
Authority
JP
Japan
Prior art keywords
compound
methyl
salt
mmol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517043A5 (enExample
Inventor
エリック、ピー、ギリス
クリスティアナ、イワグウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2023517043A publication Critical patent/JP2023517043A/ja
Publication of JP2023517043A5 publication Critical patent/JP2023517043A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022553213A 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2023517043A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062985937P 2020-03-06 2020-03-06
US62/985,937 2020-03-06
US202063040051P 2020-06-17 2020-06-17
US63/040,051 2020-06-17
PCT/IB2021/051764 WO2021176366A1 (en) 2020-03-06 2021-03-03 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2023517043A true JP2023517043A (ja) 2023-04-21
JP2023517043A5 JP2023517043A5 (enExample) 2024-03-13

Family

ID=74859494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553213A Pending JP2023517043A (ja) 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤

Country Status (12)

Country Link
US (1) US20230355626A1 (enExample)
EP (1) EP4114834A1 (enExample)
JP (1) JP2023517043A (enExample)
KR (1) KR20220151655A (enExample)
CN (1) CN115551858A (enExample)
AU (2) AU2021231447A1 (enExample)
BR (1) BR112022017832A2 (enExample)
CA (1) CA3170536A1 (enExample)
CL (1) CL2022002405A1 (enExample)
IL (1) IL296182A (enExample)
MX (1) MX2022011016A (enExample)
WO (1) WO2021176366A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) * 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
AU2014340110B2 (en) 2013-10-24 2018-07-12 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
US10221129B2 (en) 2015-04-23 2019-03-05 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
JP7433303B2 (ja) * 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
CA3170536A1 (en) 2021-09-10
CN115551858A (zh) 2022-12-30
EP4114834A1 (en) 2023-01-11
US20230355626A1 (en) 2023-11-09
WO2021176366A1 (en) 2021-09-10
BR112022017832A2 (pt) 2022-11-01
AU2024201719A1 (en) 2024-04-04
CL2022002405A1 (es) 2023-04-14
IL296182A (en) 2022-11-01
KR20220151655A (ko) 2022-11-15
MX2022011016A (es) 2022-11-30
AU2021231447A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CN114245795B (zh) 作为人类免疫缺陷病毒复制抑制剂的吡啶并[2,3-d]嘧啶衍生物
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
JP2023517043A (ja) ヒト免疫不全ウイルスの複製阻害剤
EP3853228A1 (en) Inhibitors of human immunodeficiency virus replication
ES2974657T3 (es) Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP2023517312A (ja) ヒト免疫不全ウイルスの複製阻害剤
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
US20230013823A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
ES2962774T3 (es) Inhibidores de la replicación de virus de inmunodeficiencia humana
BR122024005456A2 (pt) Compostos inibidores de replicação do vírus da imunodeficiência humana, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos no tratamento de infecção por hiv
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250606